Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Vincerx Pharma, Inc. (VINC)

0.885   -0.025 (-2.79%) 09-27 11:48
Open: 0.92 Pre. Close: 0.9104
High: 0.92 Low: 0.88
Volume: 2,954 Market Cap: 19(M)

Technical analysis

as of: 2023-09-27 11:50:51 AM
Short-term rate:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Mid-term rate:       
Target: Six months: 1.08     One year: 1.26
Support: Support1: 0.75    Support2: 0.64
Resistance: Resistance1: 0.92    Resistance2: 1.08
Pivot: 0.83
Moving Average: MA(5): 0.9     MA(20): 0.79
MA(100): 1.21     MA(250): 1.11
MACD: MACD(12,26): 0     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 87.4     %D(3): 90.6
RSI: RSI(14): 53.1
52-week: High: 1.95  Low: 0.63
Average Vol(K): 3-Month: 135 (K)  10-Days: 41 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ VINC ] has closed below upper band by 35.0%. Bollinger Bands are 21.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.92 - 0.93 0.93 - 0.93
Low: 0.82 - 0.83 0.83 - 0.83
Close: 0.91 - 0.92 0.92 - 0.93

Company Description

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.

Headline News

Tue, 19 Sep 2023
Diffuse Large B-cell Lymphoma Market to Show Immense Growth by ... - GlobeNewswire

Tue, 19 Sep 2023
Vincerx Pharma to Participate at the Cantor Fitzgerald Global ... - GlobeNewswire

Thu, 14 Sep 2023
Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial ... - GlobeNewswire

Wed, 06 Sep 2023
Triple-Negative Breast Cancer Market to Accelerate Substantially ... - PR Newswire

Fri, 01 Sep 2023
Maintenance Mirvetuximab Soravtansine Plus Bevacizumab Under ... - OncLive

Tue, 22 Aug 2023
Vincerx stock gains as FDA clears blood cancer trial - Seeking Alpha

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 21 (M)
Shares Float 16 (M)
% Held by Insiders 25.9 (%)
% Held by Institutions 60.4 (%)
Shares Short 199 (K)
Shares Short P.Month 130 (K)

Stock Financials

EPS -2.47
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.12
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -58.8
Return on Equity (ttm) -113.8
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.7
Qtrly Earnings Growth 0
Operating Cash Flow -54 (M)
Levered Free Cash Flow -34 (M)

Stock Valuations

PE Ratio -0.36
PEG Ratio 0
Price to Book value 0.78
Price to Sales 0
Price to Cash Flow -0.35

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.